Skip to main content

Regeneron: Is Eylea At Risk?

An experimental eye drug from Novartis could rival Regeneron's blockbuster drug Eylea. What does that mean for Regeneron's stock price?
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.